1603 related articles for article (PubMed ID: 33162990)
1. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
2. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
4. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Jo W; Won T; Daoud A; Čiháková D
Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
[TBL] [Abstract][Full Text] [Related]
6. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
Perazella MA; Shirali AC
Kidney Int; 2020 Jan; 97(1):62-74. PubMed ID: 31685311
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
10. Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events.
Zheng K; Qiu W; Wang H; Si X; Zhang X; Zhang L; Li X
Thorac Cancer; 2020 Jun; 11(6):1746-1751. PubMed ID: 32232975
[TBL] [Abstract][Full Text] [Related]
11. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
12. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
13. Acute Kidney Injury Induced by Immune Checkpoint Inhibitors in Lung Cancer Patients.
Lv D; He L; Guo L; Zhang X; He X
Discov Med; 2022; 33(170):137-141. PubMed ID: 36274242
[TBL] [Abstract][Full Text] [Related]
14. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
[TBL] [Abstract][Full Text] [Related]
16. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors.
Yan H; Tang M; Zhu W; Yang Y
Clin Exp Nephrol; 2023 Jul; 27(7):603-612. PubMed ID: 37014535
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
Seethapathy H; Street S; Strohbehn I; Lee M; Zhao SH; Rusibamayila N; Chute DF; Gao X; Michaelson MD; Rahma OE; Choueiri TK; McGregor B; Sonpavde G; Salabao C; Kaymakcalan MD; Wei X; Gupta S; Motwani S; Leaf DE; Reynolds KL; Sise ME
Eur J Cancer; 2021 Nov; 157():50-58. PubMed ID: 34482189
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract][Full Text] [Related]
20. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.
Guzman-Prado Y; Ben Shimol J; Samson O
Cancer Immunol Immunother; 2021 Jan; 70(1):89-100. PubMed ID: 32648164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
